APA (7th ed.) Citation

Y, M. (2026). Editorial Comment to Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study. International journal of urology : official journal of the Japanese Urological Association, 33(5), e70488. https://doi.org/10.1111/iju.70488

Chicago Style (17th ed.) Citation

Y, Miyazawa. "Editorial Comment to Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study." International Journal of Urology : Official Journal of the Japanese Urological Association 33, no. 5 (2026): e70488. https://doi.org/10.1111/iju.70488.

MLA (9th ed.) Citation

Y, Miyazawa. "Editorial Comment to Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study." International Journal of Urology : Official Journal of the Japanese Urological Association, vol. 33, no. 5, 2026, p. e70488, https://doi.org/10.1111/iju.70488.